Assertio Agrees to Enhanced All-Cash Acquisition by Garda

Assertio Therapeutics ( (ASRT) ) just unveiled an update.

Assertio Holdings, Inc. announced on May 4, 2026 that it entered into an amended and restated merger agreement on May 1, 2026 with Garda Therapeutics, which increased Garda’s all‑cash tender offer to acquire all outstanding Assertio shares to $21.80 per share, valuing the deal at about $153.2 million. The raised offer, representing a 21.1% premium to Garda’s original April 8, 2026 bid and a 63.1% premium to Assertio’s unaffected March 20, 2026 share price, was unanimously backed by Assertio’s board following a window‑shop period that included a superior proposal, and is fully supported by committed equity and debt financing, paving the way for a second‑quarter 2026 close, Nasdaq delisting, a concurrent tender for the company’s convertible notes, and the withdrawal of 2026 guidance and cancellation of the first‑quarter earnings call.

Under the revised structure, Garda will launch a majority‑acceptance tender offer, then complete a second‑step merger at the same cash price, with employee equity awards cashed out and customary conditions such as minimum net cash and regulatory clearance in place. The transaction, which carries reciprocal termination fees and support agreements with key shareholders, is expected to deliver enhanced cash value and deal certainty to Assertio investors while reinforcing Garda’s conviction in Assertio’s oncology‑focused platform and recent portfolio streamlining.

The most recent analyst rating on (ASRT) stock is a Hold with a $18.05 price target. To see the full list of analyst forecasts on Assertio Therapeutics stock, see the ASRT Stock Forecast page.

Spark’s Take on ASRT Stock

According to Spark, TipRanks’ AI Analyst, ASRT is a Neutral.

The score is held back primarily by weak financial performance, particularly the multi-year revenue decline, ongoing losses, and the 2025 shift to negative operating/free cash flow. More supportive factors include improved forward outlook from 2026 guidance tied to Robodon growth and cost reductions, plus the all-cash acquisition offer providing near-term price anchoring; technicals are moderately constructive but mixed in the short term.

To see Spark’s full report on ASRT stock, click here.

More about Assertio Therapeutics

Assertio Holdings, Inc. is a pharmaceutical company with commercial capabilities focused on marketing differentiated products primarily in the oncology market. The company recently streamlined its portfolio by selling its non‑Rolvedon assets to Cosette Pharmaceuticals on April 8, 2026, leaving Rolvedon as its core product franchise.

Average Trading Volume: 150,496

Technical Sentiment Signal: Hold

Current Market Cap: $119M

See more insights into ASRT stock on TipRanks’ Stock Analysis page.